Crucell Announces PER.C6® Licensing Agreement with Edwards Lifesciences
Dutch biotechnology company Crucell N.V. has signed a PER.C6® research license agreement with Edwards Lifesciences Corporation. The non-exclusive agreement allows Edwards to use the PER.C6® cell line for research and development of gene therapeutics based on adenoviral vectors. Under the terms of the agreement, Crucell has also granted Edwards access to technical and regulatory support. Financial details were not disclosed.
Edwards Lifesciences is a global leader in products and technologies to treat advanced cardiovascular disease and is the number-one heart valve company in the world. Headquartered in Irvine, California, Edwards focuses on specific cardiovascular opportunities including heart valve disease, peripheral vascular disease and critical care technologies.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.